Literature DB >> 3257264

Therapeutic approaches to cobalamin-C methylmalonic acidemia and homocystinuria.

D W Bartholomew1, M L Batshaw, R H Allen, C R Roe, D Rosenblatt, D L Valle, C A Francomano.   

Abstract

The use of hydroxocobalamin (OH-B12), betaine, carnitine, and folinic acid were studied in two children with the cobalamin C form of methylmalonic acidemia and homocystinuria. When daily injections of 1 mg OH-B12 were discontinued for 3 weeks, there was no significant change in total plasma homocysteine or methionine levels and only a modest increase in methylmalonate. Orally administered OH-B12 1 mg/d in one patient was associated with an increase in plasma homocystine and a decrease in methionine within 1 month. Withdrawal of betaine 250 mg/kg/d was also associated with a rise in plasma homocystine and a fall in methionine levels. Carnitine 100 mg/kg/d lead to an increase in urinary excretion of propionylcarnitine, but did not affect plasma methylmalonate levels. No beneficial biochemical effect of folinic acid could be documented at a dose of 25 mg/d. Our results suggest that daily injections of OH-B12 are not necessary to maintain metabolic control and that orally administered OH-B12 is unlikely to be effective. Betaine appears to act synergistically with OH-B12 and should be part of the treatment regimen. Although there are theoretical reasons for using L-carnitine and folinic acid, we could not document their effectiveness in these two patients.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3257264     DOI: 10.1016/s0022-3476(88)80114-8

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  23 in total

1.  Biochemical diagnosis and outcome of 2 years treatment in a patient with combined methylmalonic aciduria and homocystinuria.

Authors:  C Bellini; R Cerone; W Bonacci; U Caruso; C P Magliano; G Serra; B Fowler; C Romano
Journal:  Eur J Pediatr       Date:  1992-11       Impact factor: 3.183

2.  Clinical and biochemical observations in a patient with combined Pompe disease and cblC mutation.

Authors:  F A Wijburg; D S Rosenblatt; G D Vos; J W Oorthuys; L G van't Hek; B J Poorthuis; M K Sanders; R B Schutgens
Journal:  Eur J Pediatr       Date:  1992-02       Impact factor: 3.183

3.  The association of protein-losing enteropathy with cobalamin C defect.

Authors:  C Ellaway; J Christodoulou; R Kamath; K Carpenter; B Wilcken
Journal:  J Inherit Metab Dis       Date:  1998-02       Impact factor: 4.982

Review 4.  Biochemistry, function, and deficiency of vitamin B12 in Caenorhabditis elegans.

Authors:  Tomohiro Bito; Fumio Watanabe
Journal:  Exp Biol Med (Maywood)       Date:  2016-08-02

5.  Progressive neurological deterioration and MRI changes in cblC methylmalonic acidaemia treated with hydroxocobalamin.

Authors:  G M Enns; A J Barkovich; D S Rosenblatt; D R Fredrick; K Weisiger; C Ohnstad; S Packman
Journal:  J Inherit Metab Dis       Date:  1999-06       Impact factor: 4.982

Review 6.  Combined methylmalonic acidemia and homocystinuria, cblC type. I. Clinical presentations, diagnosis and management.

Authors:  Nuria Carrillo-Carrasco; Randy J Chandler; Charles P Venditti
Journal:  J Inherit Metab Dis       Date:  2011-07-12       Impact factor: 4.982

7.  Hemolytic uremic syndrome (HUS) secondary to cobalamin C (cblC) disorder.

Authors:  Ajay P Sharma; Cheryl R Greenberg; Asuri N Prasad; Chitra Prasad
Journal:  Pediatr Nephrol       Date:  2007-09-14       Impact factor: 3.714

8.  An indirect response model of homocysteine suppression by betaine: optimising the dosage regimen of betaine in homocystinuria.

Authors:  Angela Matthews; Trevor N Johnson; Amin Rostami-Hodjegan; Anupam Chakrapani; J Edward Wraith; Stuart J Moat; James R Bonham; Geoffrey T Tucker
Journal:  Br J Clin Pharmacol       Date:  2002-08       Impact factor: 4.335

9.  Cobalamin C Deficiency Shows a Rapidly Progressing Maculopathy With Severe Photoreceptor and Ganglion Cell Loss.

Authors:  Lucas Bonafede; Can H Ficicioglu; Leona Serrano; Grace Han; Jessica I W Morgan; Monte D Mills; Brian J Forbes; Stefanie L Davidson; Gil Binenbaum; Paige B Kaplan; Charles W Nichols; Patrick Verloo; Bart P Leroy; Albert M Maguire; Tomas S Aleman
Journal:  Invest Ophthalmol Vis Sci       Date:  2015-12       Impact factor: 4.799

10.  Methylmalonic aciduria with homocystinuria: biochemical studies, treatment, and clinical course of a Cbl-C patient.

Authors:  A Ribes; P Briones; M A Vilaseca; M Lluch; M Rodes; A Maya; J Campistol; P Pascual; T Suormala; R Baumgartner
Journal:  Eur J Pediatr       Date:  1990-03       Impact factor: 3.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.